Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status approved
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161; D04931
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 62991-2899; 69076-913; 15308-0712; 12780-0299; 0054-4581; 0378-3547
UNII E7WED276I5
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypogammaglobulinaemia10.03.02.0070.004164%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.019257%
Immune system disorder10.02.01.001--Not Available
Inflammatory bowel disease07.08.01.016--Not Available
Influenza like illness08.01.03.0100.001041%
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.002290%Not Available
Injection site haemorrhage08.02.03.005; 24.07.01.010; 12.07.03.0050.002290%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.004060%Not Available
Intestinal dilatation07.02.02.0100.001041%Not Available
Intestinal obstruction07.13.01.0020.001561%Not Available
Intestinal perforation07.04.06.002--Not Available
Intestinal stenosis07.13.01.0030.002082%Not Available
Intestinal ulcer07.04.06.003--Not Available
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.001041%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.002082%Not Available
Lactic acidosis14.01.01.0020.001041%Not Available
Large intestinal ulcer07.04.06.004--
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.004--
Leukaemia16.01.03.001; 01.10.03.001--
Leukocytosis01.02.01.0020.001561%
Leukopenia01.02.02.0010.013011%Not Available
Liver disorder09.01.08.0010.001041%Not Available
Loss of consciousness17.02.04.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoma16.20.01.001; 01.12.01.0010.001561%Not Available
Lymphopenia01.02.02.0020.002082%Not Available
Malabsorption07.17.01.001; 14.02.01.004--
Malaise08.01.01.003--
Migraine24.03.05.003; 17.14.02.001--Not Available
Mouth ulceration07.05.06.004--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene